Holen Sie sich die Stockscreener-App
144.10
2.64%
3.70
Handel nachbörslich:
144.10
Schlusskurs vom Vortag:
$140.40
Offen:
$140.76
24-Stunden-Volumen:
1.23M
Relative Volume:
1.39
Marktkapitalisierung:
$14.29B
Einnahmen:
$2.41B
Nettoeinkommen (Verlust:
$305.80M
KGV:
48.85
EPS:
2.95
Netto-Cashflow:
$492.20M
1W Leistung:
+3.22%
1M Leistung:
+12.24%
6M Leistung:
+26.57%
1J Leistung:
+18.88%
1-Tages-Spanne:
$136.49
$145.79
1-Wochen-Bereich:
$135.61
$145.79
52-Wochen-Spanne:
$84.23
$154.61
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Vergleichen Sie NBIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
144.10 | 13.93B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
153.32 | 67.90B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.40 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.80 | 44.04B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.95 | 21.20B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
400.52 | 17.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Neurocrine Biosciences Inc. recovery potential after sell offJuly 2025 Momentum & Community Consensus Picks - Newser
Tick level data insight on Neurocrine Biosciences Inc. volatilityLong Setup & Entry Point Confirmation Signals - Newser
Is Neurocrine Biosciences Inc. benefiting from interest rate changesEarnings Overview Summary & Low Risk Entry Point Tips - خودرو بانک
Can Neurocrine Biosciences Inc. generate free cash flowJuly 2025 Closing Moves & Accurate Entry/Exit Alerts - خودرو بانک
Does Neurocrine Biosciences Inc. fit your quant trading modelJuly 2025 Macro Moves & Safe Entry Momentum Tips - Newser
Neurocrine Biosciences: RBC Capital maintains Outperform, raises PT to $149. - AInvest
RBC Raises Price Target on Neurocrine Biosciences to $149 From $144, Keeps Outperform Rating - MarketScreener
What’s next for Neurocrine Biosciences Inc. stock priceWeekly Profit Summary & Reliable Intraday Trade Alerts - Newser
Will Neurocrine Biosciences Inc. benefit from current market trendsMarket Growth Review & Weekly Consistent Profit Watchlists - خودرو بانک
Will Neurocrine Biosciences Inc. price bounce be sustainable2025 Key Lessons & Long-Term Capital Growth Strategies - Newser
Is Neurocrine Biosciences Inc. a cyclical or defensive stockJuly 2025 Breakouts & Weekly Return Optimization Alerts - خودرو بانک
Will Neurocrine Biosciences Inc. stock go up soonJuly 2025 Volume & Community Consensus Picks - Newser
Neurocrine at Cantor Global Healthcare Conference: Strategic Insights on Growth - Investing.com Canada
Neurocrine Biosciences Inc. stock retracement – recovery analysis2025 Stock Rankings & AI Forecasted Stock Moves - Newser
What are Neurocrine Biosciences Inc.’s growth leversPortfolio Gains Summary & AI Powered Buy and Sell Recommendations - خودرو بانک
What’s the recovery path for long term holders of Neurocrine Biosciences Inc.July 2025 Analyst Calls & Intraday High Probability Setup Alerts - Newser
Can Neurocrine Biosciences Inc. hit a new high this monthPortfolio Return Summary & Safe Capital Growth Stock Tips - Newser
Does Neurocrine Biosciences Inc. have pricing powerJuly 2025 Update & Fast Momentum Stock Entry Tips - خودرو بانک
Neurocrine Biosciences Shares Dip 4.09% on Strong Volume Surge to 478th Rank Amid Q2 Earnings Boost - AInvest
Neurocrine Biosciences' Strategic Position in the CNS Therapeutics Market - AInvest
Transcript : Neurocrine Biosciences, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-03-2025 01 - MarketScreener
Does Neurocrine Biosciences Inc. qualify in momentum factor screeningJuly 2025 Big Picture & Stepwise Entry and Exit Trade Signals - Newser
Endometriosis Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine - Barchart.com
What to expect from Neurocrine Biosciences Inc. in the next 30 daysJuly 2025 Final Week & Accurate Buy Signal Alerts - Newser
Is a relief rally coming for Neurocrine Biosciences Inc. holdersMarket Performance Recap & Breakout Confirmation Alerts - Newser
Will Neurocrine Biosciences Inc. stock recover after recent dropBull Run & Weekly Top Gainers Trade List - Newser
Risk vs reward if holding onto Neurocrine Biosciences Inc.July 2025 Volume & Trade Opportunity Analysis Reports - Newser
Custom watchlist performance reports with Neurocrine Biosciences Inc.Portfolio Profit Report & Real-Time Buy Zone Alerts - Newser
Neurocrine Biosciences Inc. stock trendline breakdownIndex Update & Free Technical Confirmation Trade Alerts - Newser
Long term hold vs stop loss in Neurocrine Biosciences Inc.2025 Volatility Report & Real-Time Chart Pattern Alerts - Newser
Will Neurocrine Biosciences Inc. stock hit new highs in YEARQuarterly Market Review & Stock Market Timing Techniques - خودرو بانک
Is Neurocrine Biosciences Inc. showing signs of accumulation2025 Top Gainers & Fast Gaining Stock Reports - Newser
Is Neurocrine Biosciences Inc. being accumulated by smart moneyJuly 2025 Levels & Fast Entry and Exit Trade Plans - خودرو بانک
Technical Bounce Expected in Neurocrine Biosciences Inc. Next Week getLinesFromResByArray error: size == 0 - thegnnews.com
Neurocrine Biosciences, Inc. (NBIX) Beats Estimates on Neurology Drug Demand, Expands Payer Access - Yahoo Finance
Is Neurocrine Biosciences Inc. forming a reversal patternVolume Spike & Reliable Price Action Trade Plans - Newser
Understanding Neurocrine Biosciences Inc.’s price movement2025 Technical Patterns & High Yield Stock Recommendations - Newser
Real time social sentiment graph for Neurocrine Biosciences Inc.Jobs Report & Weekly Breakout Opportunity Watchlist - Newser
Tools to monitor Neurocrine Biosciences Inc. recovery probabilityTrade Ideas & AI Enhanced Trading Signals - Newser
Historical volatility pattern of Neurocrine Biosciences Inc. visualizedMarket Performance Recap & Low Drawdown Investment Ideas - Newser
Will Neurocrine Biosciences Inc. outperform small cap indexes2025 Historical Comparison & Real-Time Volume Trigger Notifications - 선데이타임즈
How Neurocrine Biosciences Inc. stock performs during market volatilityMarket Growth Summary & Weekly Setup with High ROI Potential - Newser
How to integrate Neurocrine Biosciences Inc. into portfolio analysis toolsEarnings Miss & Technical Entry and Exit Alerts - Newser
Ranking Neurocrine Biosciences Inc. among high performing stocks via tools2025 Macro Impact & Verified Momentum Stock Ideas - Newser
What Fibonacci levels say about Neurocrine Biosciences Inc. reboundProduct Launch & Verified High Yield Trade Plans - Newser
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neurocrine Biosciences Inc-Aktie (NBIX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GORMAN KEVIN CHARLES | Director |
Aug 07 '25 |
Sale |
126.41 |
106,322 |
13,440,281 |
514,596 |
1.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):